U.S. stock market midday update: Equillium down 13.53%, trading volume increased, market sentiment fluctuations attract attention

U.S. Stock Market Midday Update

Equillium, down 13.53%, with increased trading volume and no significant news recently. Trading is active, with clear capital flow. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

Stocks with High Trading Volume in the Industry

Regeneron Pharmaceuticals down 10.32%. Based on recent key news:

1. On May 18, Regeneron Pharmaceuticals announced that its investigational drug fianlimab in combination with Libtayo for the treatment of melanoma did not meet the primary endpoint in a Phase 3 clinical trial, leading to a sharp decline in stock price. The trial results showed that although the median progression-free survival improved, it did not achieve statistical significance, causing the stock to drop over 11% in pre-market trading. Source: Zhitong Finance

2. On May 18, multiple investment banks downgraded Regeneron Pharmaceuticals' rating and target price. Leerink lowered its rating from "Outperform" to "Market Perform," and reduced the target price from $792 to $641. Source: Wall Street Insight

3. On May 18, analysts generally lowered the target price for Regeneron Pharmaceuticals. JP Morgan cut its target price from $950 to $850, and Piper Sandler reduced its target price from $875 to $855. Source: Jinshi Data. The biopharmaceutical industry has seen increased volatility recently, which requires attention.

GeoVax Labs, up 115.85%, with trading volume reaching $604 million, a 60-day high, and no significant news recently. Trading is active, with clear capital flow. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

Sunshine Biopharma up 104.15%. Based on recent key news:

1. On May 18, Sunshine Biopharma's stock price surged 561.74% in pre-market trading, following a 39.46% drop the previous Friday. The company's stock price has fallen 76.9% year-to-date and 80.93% over the past 12 months. The significant increase in trading volume indicates a potential short squeeze.

2. On May 18, the company announced that while it is optimistic about future performance, it cannot guarantee future results, performance, or achievements. The company has historically conducted reverse stock splits to boost its stock price and avoid delisting, which serves as a warning signal for investors.

3. On May 18, the company issued a press release via ACCESS Newswire, emphasizing its expectations for future performance but did not commit to updating any forward-looking statements to align with actual results. The increased trading volume and clear capital flow indicate potential risks that need attention.

Stocks with High Market Capitalization in the Industry

AbbVie down 1.16%. Based on recent news,

1. On May 18, MarketBeat noted that although AbbVie received a moderate buy rating from analysts, top analysts preferred to recommend five other stocks, which may weaken investor confidence in AbbVie, leading to a decline in stock price

2. On May 17th, MarketBeat's report emphasized that AbbVie was not included in the list of five stocks recommended by analysts, further weakening market confidence in it and putting pressure on its stock price.

3. On May 16th, market attention towards AbbVie decreased, failing to attract active buying from investors, which affected its stock price performance. Market attention towards the pharmaceutical sector has diminished